scholarly journals Retrospective Analysis of Culture-Positive Peripherally Inserted Central Catheter Infections at an Academic Medical Center

2012 ◽  
Vol 33 (10) ◽  
pp. 1063-1064
Author(s):  
Christina Liscynesky ◽  
Kurt B. Stevenson
2016 ◽  
Vol 21 (4) ◽  
pp. 230-236 ◽  
Author(s):  
Eric J. Keller ◽  
Edouard Semaan ◽  
Jung Lee ◽  
Emily Aragona ◽  
Heather Molina ◽  
...  

AbstractBackground: To assess the technical success of ultrasound (US)-guided peripherally inserted central catheter (PICC) placement at a large academic medical center and evaluate the direct and indirect costs associated with malpositioned catheters.Methods: This retrospective chart review consisted of 250 consecutive inpatients and 150 consecutive outpatients (N = 400, aged 58 ± 17 years, 225 men and 175women) who underwent US-guided PICC placement at a single center. Repositioning rates were compared between high-complexity (inpatient) and low-complexity (outpatient) groups using a χ2 test and phi coefficient. Initial and final catheter tip position was assessed by radiography. Direct costs of repositioning were estimated using Medicare reimbursement rates. Indirect costs, including additional staff time, imaging, and delays in treatment, were assessed via a survey of PICC nurses and chart reviews.Results: Initial PICC placement resulted in an optimal tip position in 34% of patients and an optimal or acceptable position in 84% of patients. Repositioning rates were significantly higher for inpatients with a low to moderate association between inpatient PICC placement and the need for repositioning (χ2 = 9.603, P = .002; σ = 0.155, P = .002). In total, 77 catheters required repositioning, costing on average an additional $186.03 and 50 minutes of staff time per catheter as well as delaying catheter use in 23 patients for at least 24 hours.Conclusions: PICC malpositioning is a significant source of inefficiency, especially for inpatient services, that should be addressed to reduce expenditures and maximize patients' perceptions of quality health care.


2013 ◽  
Vol 69 (4) ◽  
pp. 654-657 ◽  
Author(s):  
Alisa N. Femia ◽  
A. Brooke Eastham ◽  
Christina Lam ◽  
Joseph F. Merola ◽  
Abrar A. Qureshi ◽  
...  

2020 ◽  
Vol 7 (10) ◽  
Author(s):  
Jeffrey C Pearson ◽  
Brandon Dionne ◽  
Aaron Richterman ◽  
Samuel J Vidal ◽  
Zoe Weiss ◽  
...  

Abstract Background Omadacycline is an aminomethylcycline antimicrobial approved by the US Food and Drug Administration in 2018 for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It has in vitro activity against nontuberculous mycobacteria, including Mycobacterium abscessus complex, but clinical data for this indication are lacking. Methods Omadacycline use was reviewed at an 804-bed academic medical center. Patients were included if they received omadacycline for culture-proven M abscessus disease in 2019. Results Four patients received omadacycline for the treatment of culture-positive M abscessus disease in 2019. Two patients had cutaneous disease, 1 had pulmonary disease, and 1 had osteomyelitis and bacteremia. The patients received omadacycline for a median duration of 166 days (range, 104–227) along with a combination of other antimicrobial agents. Omadacycline-containing regimens were associated with a clinical cure in 3 of 4 patients, with 1 patient improving on ongoing treatment. Omadacycline’s tolerability was acceptable for patients with M abscessus disease, with 1 patient discontinuing therapy in month 6 due to nausea. Conclusions Omadacycline is a novel oral option for the treatment of M abscessus disease, for which safe and effective options are needed. Although this case series is promising, further data are required to determine omadacycline’s definitive role in the treatment of M abscessus disease.


Sign in / Sign up

Export Citation Format

Share Document